Skip to main content
Heather Nichols, MD, Pediatrics, Oxnard, CA

Heather F Nichols MD FAAP (She/Her)


Pediatrician at Coastal Pediatric Medical Group

Join to View Full Profile
  • 451 W Gonzales RdSte 340Oxnard, CA 93036

  • Phone+1 805-983-3900

  • Fax+1 805-983-3887

Dr. Nichols is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Heather Nichols is a Pediatrician based in Oxnard, CA. She attained her MD from Drexel University College of Medicine in 2003 and completed her residency in Pediatrics at Brown University from 2003-2006. She also holds a MA in Bioethics from Case Western Reserve University (1997-1998). She currently works as a General Pediatrician at Community Memorial Hospital, a role she has held since 2013. Prior to this, she was a General Pediatrician at Ventura County Medical Center for ten years (2003-2013).

Education & Training

  • Brown University
    Brown UniversityResidency, Pediatrics, 2003 - 2006
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 2003
  • Case Western Reserve University
    Case Western Reserve UniversityMA, Bioethics, 1997 - 1998

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2006 - 2026
  • RI State Medical License
    RI State Medical License 2005 - 2006
  • Pediatrics
    American Board of Pediatrics Pediatrics

Press Mentions

  • Vertex and CRISPR Therapeutics Announce Global Exa-Cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
    Vertex and CRISPR Therapeutics Announce Global Exa-Cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022September 27th, 2022
  • Vertex and CRISPR Therapeutics Present New Data in 22 Patients with Greater Than 3 Months Follow-up Post-Treatment with Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
    Vertex and CRISPR Therapeutics Present New Data in 22 Patients with Greater Than 3 Months Follow-up Post-Treatment with Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual MeetingJune 11th, 2021
  • CRISPR Therapeutics Receives Grant to Advance in Vivo CRISPR/Cas9 Gene Editing Therapies for HIV
    CRISPR Therapeutics Receives Grant to Advance in Vivo CRISPR/Cas9 Gene Editing Therapies for HIVDecember 7th, 2020
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: